Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2015

  • ID: 3266305
  • Company Profile
  • 141 pages
  • Global Markets Direct
  • Teva Pharmaceutical Industries Ltd.
1 of 4
Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2015

Summary

This, ‘Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2015’, provides an overview of the Teva Pharmaceutical Industries Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Teva Pharmaceutical Industries Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Teva Pharmaceutical Industries Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Teva Pharmaceutical Industries Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Teva Pharmaceutical Industries Limited’s pipeline products

Reasons to buy

- Evaluate Teva Pharmaceutical Industries Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Teva Pharmaceutical Industries Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Teva Pharmaceutical Industries Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Teva Pharmaceutical Industries Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Teva Pharmaceutical Industries Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Teva Pharmaceutical Industries Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Teva Pharmaceutical Industries Limited Snapshot
Teva Pharmaceutical Industries Limited Overview
Key Information
Key Facts
Teva Pharmaceutical Industries Limited - Research and Development Overview
Key Therapeutic Areas
kTeva Pharmaceutical Industries Limited - Pipeline Review
Teva Pharmaceutical Industries Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Teva Pharmaceutical Industries Limited - Pipeline Products Glance
Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products
Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products
Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products
Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products
Teva Pharmaceutical Industries Limited - Drug Profiles
(ethinylestradiol + levonorgestrel)
glatiramer acetate
hydrocodone bitartrate ER
laquinimod sodium
lipegfilgrastim
(fluticasone propionate + salmeterol xinafoate)
albutropin
armodafinil
beclomethasone dipropionate
bendamustine hydrochloride
fluticasone propionate
pridopidine hydrochloride
rasagiline mesylate
reslizumab
omacetaxine mepesuccinate
TEV-48125
TV-1380
TV-45070
atropine sulfate
CEP-37250
CEP-37440
irdabisant
TEV-90110
TEV-90112
TV-46017
TV-46139
TV-46763
TV-48108
CEP-11981
CEP-28122
CEP-33779
Drug for Undisclosed Indication
MDT-011
MetPril
modafinil next generation
NP-201
NP-202
Recombinant Protein to Inhibit IL-17A for Psoriasis
Recombinant Protein to Target CD38 for Multiple Myeloma
Small Molecule-2 to Antagonize 5-HT6 for CNS Disorders
(acetaminophen + immediate release opioid 1)
(acetaminophen + immediate release opioid 2)
AD-3
AD-4
Fixed Dose Combination-3 for HIV
Fixed Dose Combination-4 for HIV
risperidone LAI
Small Molecule to Inhibit Poly (ADP-Ribose) Polymerase 1 for Undisclosed Indication
Small Molecule-1 to Antagonize 5-HT6 Receptor for CNS Disorders
Drug for Dependence
Drug For Parkinson Disease
Teva Pharmaceutical Industries Limited - Pipeline Analysis
Teva Pharmaceutical Industries Limited - Pipeline Products by Target
Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration
Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates
Teva Pharmaceutical Industries Limited - Dormant Projects
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Teva Pharmaceutical Industries Limited - Company Statement
Teva Pharmaceutical Industries Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Teva Pharmaceutical Industries Limited, Key Information
Teva Pharmaceutical Industries Limited, Key Facts
Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2015
Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2015
Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2015
Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2015
Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2015
Teva Pharmaceutical Industries Limited - Partnered Products/ Combination Treatment Modalities, 2015
Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2015
Teva Pharmaceutical Industries Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015
Teva Pharmaceutical Industries Limited - Pre-Registration, 2015
Teva Pharmaceutical Industries Limited - Filing rejected/Withdrawn, 2015
Teva Pharmaceutical Industries Limited - Phase III, 2015
Teva Pharmaceutical Industries Limited - Phase II, 2015
Teva Pharmaceutical Industries Limited - Phase I, 2015
Teva Pharmaceutical Industries Limited - Preclinical, 2015
Teva Pharmaceutical Industries Limited - Discovery, 2015
Teva Pharmaceutical Industries Limited - Unknown, 2015
Teva Pharmaceutical Industries Limited - Pipeline by Target, 2015
Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2015
Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2015
Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action, 2015
Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2015
Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2015
Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2015
Teva Pharmaceutical Industries Limited, Other Locations
Teva Pharmaceutical Industries Limited, Subsidiaries

List of Figures
Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Indication, 2015
Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2015
Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2015
Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2015
Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2015
Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Target, 2015
Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Route of Administration, 2015
Teva Pharmaceutical Industries Limited - Pipeline by Top 10 Molecule Type, 2015
Teva Pharmaceutical Industries Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll